Incidence, Treatment and Outcomes of Patients with Synchronous Lung and Colorectal Malignancies: A Nationwide Inpatient Sample Database (NIS) Analysis

Incidence, Treatment and Outcomes of Patients with Synchronous Lung and Colorectal Malignancies: A Nationwide Inpatient Sample Database (NIS) Analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Incidence, Treatment and Outcomes of Patients with Synchronous Lung and Colorectal Malignancies: A Nationwide Inpatient Sample Database (NIS) Analysis Alejandro Cruz, Mohammad Afaque Alam, Pamela Omesiete, Sabina Saeed, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4971114/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Purpose: Our study aims to describe the incidence, treatment and clinical outcomes of patients with synchronous lung, and colorectal cancer (CRC). Methods: We conducted an 11-years analysis of the Nationwide Inpatient Sample (NIS) database (2002–2012). All adult (age ≥ 18y) patients admitted with a diagnosis of CRC were included. Data abstracted include demographics, malignancy-related variables, treatment, and operative interventions. We excluded patients who had lung metastasis from CRC. Our primary outcome measures were the incidence of synchronous CRC and lung cancer, operative treatment patterns, and mortality. Results: Out of 1,198,421 patients admitted with a CRC diagnosis, 6,231 (0.52%) had synchronous lung cancer. Overall, mean age was 61 ± 15y, 75% were male, and 63% were white. Most patients with synchronous malignancies (56%) had advanced CRC with non-small cell lung cancer (76%). The majority of CRC patients (79%) had recto-sigmoid tumors. Only 11.2% underwent surgical management. No significant difference was noted in the proportion of patients first treated for their CRC relative to those treated for their lung cancer first (p = 0.21). The overall mortality rate was 54%. Conclusion: The incidence of synchronous occurrence of CRC and lung cancer is low, but the mortality is very high. Diagnosis of synchronous cancer is typically incidental. Treatment options for these patients should be tailored to the individual patient. Genetic and epidemiological studies are required to elucidate the potential connection between lung and colon cancer. Synchronous Colorectal Lung Cancer Figures Figure 1 INTRODUCTION Lung Cancer (LC) remains the leading cause of cancer-related deaths, with Colorectal Cancer (CRC) being the third leading cause of cancer-related deaths in the US [ 1 , 2 ]. Patients diagnosed with metastatic CRC may have tumors arising in locations such as the liver, lungs, and peritoneum [ 3 ]. Although CRC and lung cancer are among the most common cancers worldwide, synchronous presentation of these cancers are not very common and not well studied. Clinically, synchronous cancers refer to the onset of a second primary cancer within 6 months of an initial cancer diagnosis or co-occurring. Although the condition is uncommon, there has been a rise in synchronous CRC cases in recent years. Insufficient data is available on the onset of synchronous cancer that this disease remains poorly understood [ 4 ]. The rarity of this clinical presentation at the onset can often lead to delay of treatment or misdiagnosis of metastasis, rather than finding the cancers to be coinciding [ 13 ]. Improvements in diagnostic modalities have contributed to the increased detection of synchronous CRCs [ 4 ]. Reported incidences range from 2.3–12.4%. [ 4 ] Additionally, the prevalence of synchronous CRC ranges from 1.1–8.1% among all CRCs [ 5 ]. Despite the increased prevalence of the disease, the most appropriate treatment options, including surgical, remain uncertain. Previous studies have shown that the treatment for synchronous cancer is different in that it is done according to the distribution of lesions [ 4 ]. Synchronous CRC differs from single origin cancer with regards to gender, age, location, as well as pathologic features [ 4 ]. Risk factors for this disease include inflammatory bowel disease, familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, hyperplastic polyposis, and microsatellite instability [ 6 , 7 ]. A few case studies have demonstrated synchronous CRC in patients with liver, kidney, prostate, and lung cancers [ 8 – 11 ]. A majority of synchronous CRC cancers occur in the liver, followed by the lung [ 20 ]. Few case reports have indicated synchronous CRC and LC with lesions located in the rectum and the lungs; nonetheless, this identified patient population remains low, and outcomes in patients with synchronous lung and CRC are not well described [ 11 ]. Our study aimed to describe the incidence, treatment, and outcomes of patients with synchronous lung and CRC. It is important to develop a better understanding of synchronous lung and CRC in order to further advance treatment options for those affected. METHODS Dataset We used the Nationwide Inpatient Sample (NIS) to analyze data from 2002 to 2012 retrospectively. The NIS is one of the largest all-payer national databases in the United States developed and maintained as a part of the Health Care Cost and Utilization Project (HCUP). The NIS database includes inpatient care information from community hospitals, and teaching medical centers; however, this database does not include data from long-term facilities. Every year, the NIS provides information on nearly 7 million unweighted discharges nationally. The use of the NIS database for this study followed regulations according to the data-use agreement from the HCUP. Ultimately, this study was reviewed by the University of Arizona’s Institutional Review Board and was determined to be exempt from the need for approval. Figure 1 shows a flowchart classifying patients based on the development of colorectal cancer (CRC) alone or synchronous CRC with simultaneous lung cancer from 2002 to 2012, as listed in the NIS database. Among the 1,198,421 patients admitted with a CRC diagnosis, 6,231 had synchronous lung cancer. The patients were further categorized by tumor stage and treatment strategies. Patient population and Stratification Patients older the age of 18 presenting with CRC alone or synchronous CRC with simultaneous Lung Cancer were included in this study. Additionally, the codes for colon, rectal, and lung cancer were used for stratification using Ninth Revision of the International Classification of Disease Diagnosis (ICD-9 codes). To ascertain that only synchronous lung cancer patients were analyzed, metastatic lung cancer patients were excluded from the analysis. Thus, patients with ICD-9 CM code 197.0 were excluded from the analysis. 197.0: Secondary malignant neoplasm of the lung. Variables analyzed and Outcome Measures From the database analysis, we retrieved information on patient demographics (age, gender, race), insurance (Medicare, Medicaid, private/self-pay, other), income (lowest quartile vs. highest quartile), CRC location (hepatic flexure, transverse colon descending colon, sigmoid colon, cecum, appendix , ascending colon, splenic flexure, rectosigmoid, rectum, and anus), tumor stage (I, II, III, IV), treatment (chemotherapy, radiotherapy, colectomy, lobectomy), as well as treatment sequence (treatment of CRC first versus treatment of lung cancer first or supportive care alone). Statistical analysis Data with a normal distribution is reported as mean ± standard deviation (SD) for continuous variables, as median [interquartile range (IQR)] for continuous variables without normal distribution, and as proportions (% percentage) for the categorical variables. To analyze the differences between the two patient groups, we used a chi-square test for categorical variables, the Mann-Whitney U test for continuous nonparametric data, and an independent Student’s t-test for continuous parametric data. A multivariate logistic regression was used to control for the following covariates: patient’s demographics, type of cancer, location of tumor, and the treatment sequencing and modality. First, we assessed the association between each covariate and the binary outcomes on a univariate level. Variables detected to have a p-value < 0.2 after performing the univariate analysis were selected for inclusion in the multivariable logistic regression model. Hosmer-Lemeshow goodness of fit test was used to assess the model fitness. The Hosmer-Lemeshow test exceeded 0.05 and the tolerance was greater than 0.1 for all independent variables with a variance inflation factor of less than 10.0. In this study, alpha was set at 5% and a value of p < 0.05 was considered statistically significant. All statistical analyses in our study were performed using the Statistical Package for Social Sciences (SPSS, version 24; SPSS, Inc). RESULTS A total of 1,198,421 patients were admitted to a hospital with a diagnosis of CRC of which 6,231 were found to have synchronous lung cancer. In Table 1 , the demographics in patients who presented with CRC alone and synchronous CRC and Lung cancers were similar in average age, gender, whites, BMI, Medicare and Medicaid. There was a significant difference in patients with private insurance with about 8% with CRC alone versus 12% with synchronous CRC and Lung Cancer (p = 0.01). In addition, there was a statistically significant difference in patients in the low-income quartile (24% vs 26%). Table 1: Baseline Characteristics of the Study Sample Variable CRC N=1,192,189 CRC + Lung Cancer N=6,231 P-Value Demographics Age, years ± SD 60±14 61±11 0.32 Male, % 75% 74% 0.11 White, % 67% 68% 0.38 BMI≥30 kg/m 2 33% 27% 0.74 Medicare 62% 61% 0.63 Medicaid 30% 27% 0.87 Private Insurance 8% 12% 0.01* Low Income Quartile 24% 26% 0.01* CRC Location, % Hepatic Flexure 2.5% 2.6% 0.17 Transverse Colon 4.8% 2.9% 0.06 Descending Colon 2.5% 10% <0.01* Sigmoid Colon 8% 6% 0.06 Cecum 9% 7.5% 0.64 Appendix 2% 0.3% 0.13 Ascending Colon 10% 6.2% 0.87 Splenic Flexure 2% 1% 0.32 Rectosigmoid 79% 78% 0.14 Rectum 6% 8% 0.56 Anal 2.4% 2.9% 0.74 Unspecified 0.8% 2.4% 0.01* * p-values <0.05 is statistically significant Most CRC patients (79%) had recto-sigmoid tumors. On the other hand, in synchronous CRC and lung cancer, the CRC location most involved was the descending colon (10%) and in unspecified locations (2.4%) when being compared to CRC cancer alone (p < 0.01). Additionally, most patients with synchronous malignancies (56%) had advanced CRC with non-small cell lung cancer (p < 0.01). In Table 2 , the analysis also showed that there were more patients diagnosed with stage II CRC cancer alone (42%) compared to those with synchronous CRC cancer and lung cancer (17%). Table 2 Tumor Stage of the Study Sample Tumor Stage CRC N = 1,192,189 CRC + Lung Cancer N = 6,231 P-Value I 6% 4% 0.09 II 42% 17% < 0.01* III 21% 23% 0.77 IV 31% 56% < 0.01* * p-values < 0.05 is statistically significant In Table 3 , the majority of the patients with synchronous CRC cancer and lung cancer (54%) were treated with chemotherapy (P < 0.01) while just 15% of this cohort of patients had a colectomy. In Table 4 , no significant difference was noted in the proportion of patients first treated for their CRC relative to those treated for their lung cancer first (p = 0.21). Overall, there was a statistically significant difference in the mortality rate for synchronous CRC and lung cancer versus CRC alone (65% vs 54%). Table 3 Treatments of the Study Sample Treatment CRC N = 1,192,189 CRC + Lung Cancer N = 6,231 P-Value Chemotherapy 36% 54% < 0.01* Radiotherapy 17% 16% 0.07 Colectomy 25% 15% < 0.01* Lobectomy - 16% * p-values < 0.05 is statistically significant Table 4 Treatment Sequence of the Study Sample Treatment Sequence CRC + Lung Cancer N = 6231 Treatment of Colon Cancer First 12% Treatment of Lung Cancer First 13% Supportive Care Alone 75% Table 5 Outcomes for Study Sample Outcomes CRC N = 1,192,189 CRC + Lung Cancer N = 6,231 P-Value Mortality, % 54% 65% < 0.01* * p-values < 0.05 is statistically significant DISCUSSION Our study showed that synchronous CRC and lung cancer is not very common but has a significant mortality rate. The independent risk factors for CRC or lung cancer have previously been established. Cigarette smoking has been shown as a generally accepted risk factor, especially within lung cancer [ 11 ]. Previous studies have also demonstrated that obesity, diabetes, and high dietary meat intake are associated with an increased risk of colon cancer [ 11 ]. Multiple risk factors have also been found to contribute to the development of synchronous CRC. African American race, advanced age, high primary tumor grade and size, perineural invasion, elevated CEA, and existing liver metastasis are associated with synchronous CRC and lung tumors [ 20 ]. The results of our study showed some differences when it comes to demographic factors that influence CRC and synchronous CRC and lung tumors (Table 1 ). Previous studies have also indicated a higher incidence of synchronous CRC among men, especially in patients over 70 years [ 14 ]. Our study further reinforces this significance, as the data shows a higher percentage of men (74%) than women are diagnosed with synchronous CRC and lung cancer. In our study, the average age of diagnosis for CRC alone or synchronous with lung cancer was around 60 and primarily occurring mostly in white individuals. Interestingly, our data showed that patients with private insurance and those within the low-income quartile were more likely to have synchronous CRC than CRC alone, which was statistically significant. This could be because the patients in low-income quartile might have more comorbidities due to poor health choices and because they might have less access to healthcare. Regarding location, synchronous CRC with LC arises more commonly in the descending colon and unspecified areas in our group of patients. This differs from metastatic CRC to the lung. Previous studies have shown that rectal and left-sided colon cancer had more predilection for lung metastasis over other sites, such as liver and peritoneum (16). It is important to consider the different venous drainage systems of the colon—the inferior rectum is drained to the systemic circulation via the inferior rectal veins while the rest of the colon drains to the portal system. This may explain why rectal tumors more commonly have metastasis to the lungs [ 19 ]. Our study demonstrates that more than half the patients diagnosed with synchronous CRC and lung cancer had advanced-stage disease. This might be because these patients might have a more aggressive disease or have a predilection for cancer. The majority of synchronous CRC and lung cancer patients (75%) undergone supportive care alone. This is quite understandable because these patients had significantly advanced diseases. These patients were also more likely to undergo chemotherapy (54%) than colectomy (15%). Lung lobectomy was performed in 16% of the individuals with synchronous lung and CRC. Overall, synchronous CRC and lung cancer were found to have higher mortality rates than CRC alone. A previous study investigating treatment outcomes in synchronous CRC with lung cancer patients found that subjects who had undergone lung tumor resection had overall better survival than those who did not, with a hazard ratio of 0.482 [ 17 ]. We were not able to determine this particular outcome in our study. Another study showed that synchronous CRC patients who had undergone pulmonary metastasectomy had a 65% 5-year survival rate [ 18 ]. However, this study looked more are pulmonary metastasis and not primary lung cancer. Regarding the treatment sequence, our study showed 12% of patients with synchronous CRC and lung cancer underwent treatment of their colorectal cancer first. In comparison, 13% underwent treatment for their lung cancer first. As previously mentioned, most patients underwent supportive care alone. In our study, we could not determine whether any of the patients underwent concurrent management of both lung and colorectal cancer. We assume that this possibly happened. Information on the time interval between colon resections and lobectomies was not available. In one case report study of synchronous CRC and lung cancer in a patient with adenocarcinoma in both locations, confirmed using immunostaining showing primary origins in each location, the patient underwent lobectomy and months later a colon resection was performed [ 15 ]. This showed that both surgical procedures could be performed in a sequential manner. Our study also demonstrates that patients with synchronous CRC and lung cancer have a higher mortality rate than those diagnosed with CRC alone (65% vs 54%). Our results are concurrent with other synchronous cancer studies, which have demonstrated worse outcomes of survival for synchronous CRC compared to CRC alone [ 14 ]. Due to lung cancer being the leading cause of cancer-related deaths in the US, this can be considered a contributing factor to the high mortality rate observed within synchronous cancer [ 2 ]. One study of 3,102 patients followed over 76 months found that of the 9 patients that succumbed to their illness, all 9 deaths were directly associated to the patients’ lung cancer [ 11 ]. Advanced staging (56%) can be another contributor to why higher mortality rates are seen amongst patients with synchronous CRC and lung cancer, as shown in our results. Our analysis shows that patients with synchronous CRC and lung cancer are more likely to present with stage IV than CRC alone. One of the inherent limitations of this study is that it is a retrospective analysis and there might be missing data. We could not review the histopathology of the CRC or lung cancer to determine synchronous primary lung cancer from metastatic lung cancer. However, we excluded from this study all the lung cancers that were coded with ICD-9 CM code 197.0, which represents metastatic disease to the lungs. Another limitation of this study was the lack of staging of primary lung cancer. The assumption would have been that a higher stage of lung cancer will likely have more contribution to patient mortality. This would have also been important in determining if the high mortality in the synchronous lung and colorectal cancer was due to colorectal cancer or lung cancer. Given the fact that lung cancer is the leading cause of cancer-related deaths in the US, it is reasonable to conclude a higher stage of synchronous lung cancer is more predictive of mortality than colorectal cancer is. CONCLUSION The incidence of synchronous occurrence of CRC and lung cancer is low, but the mortality is very high. Diagnosis of synchronous cancer is typically incidental. These patients usually present with more advanced disease and mortality might likely be accentuated by lung cancer. Treatment options for these patients should be tailored to the individual patient. Genetic and epidemiological studies are required to elucidate the potential connection between lung and colon. Declarations Funding: No financial or proprietary interest in the subject matter or materials discussed in the manuscript. Conflicts of interest/Competing interest: There are no conflicts of interests to report. Availability of data and material: Nationwide Inpatient Sample database (2002-2012) Code availability: ICD-9 CM code 197.0 Author’s contribution: Study Design and Conception: VN, MAA, PO, AC, MH, SS, MA, MG Data Acquisition: MAA, PO, AC, VN, MH Statistical Analysis: MH, MAA Manuscript Writing: MAA, AC, VN, PO, MH, SS, MA, MG Critical Revision: VN, MAA, AC, PO, MH, SS, MA, MG Final Approval: VN, MAA, AC, PO, MH, SS, MA, MG * Contributed Equally (AC and MAA). References Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. http://doi.org/10.3322/caac.21590 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. http://doi.org/10.3322/caac.21551 Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765. Published 2016 Jul 15. http://doi.org/10.1038/srep29765 Lee BC, Yu CS, Kim J, et al. Clinicopathological features and surgical options for synchronous colorectal cancer. Medicine (Baltimore). 2017;96(9):e6224. http://doi.org/10.1097/MD.0000000000006224 He W, Zheng C, Wang Y, et al. Prognosis of synchronous colorectal carcinoma compared to solitary colorectal carcinoma: a matched pair analysis. Eur J Gastroenterol Hepatol. 2019;31(12):1489-1495. http://doi.org/10.1097/MEG.0000000000001487 Chin CC, Kuo YH, Chiang JM. Synchronous colorectal carcinoma: predisposing factors and characteristics. Colorectal Dis. 2019;21(4):432-440. http://doi.org/10.1111/codi.14539 Lam AK, Chan SS, Leung M. Synchronous colorectal cancer: clinical, pathological and molecular implications. World J Gastroenterol. 2014;20(22):6815-6820. http://doi.org/10.3748/wjg.v20.i22.6815 Burlaka AA, Kolesnik OO. Parenchyma sparing multicomponent liver resection strategy for multiple bilobar synchronous colorectal cancer metastasis. Clin Case Rep. 2020;8(4):661-666. Published 2020 Feb 26. http://doi.org/10.1002/ccr3.2742 Sakellakis M, Peroukides S, Iconomou G, Boumpoucheropoulos S, Kalofonos H. Multiple primary malignancies: a report of two cases. Chin J Cancer Res. 2014;26(2):215-218. http://doi.org/10.3978/j.issn.1000-9604.2014.02.15 Jacobs CD, Trotter J, Palta M, et al. Multi-Institutional Analysis of Synchronous Prostate and Rectosigmoid Cancers. Front Oncol. 2020;10:345. Published 2020 Mar 24. http://doi.org/10.3389/fonc.2020.00345 Kurishima K, Miyazaki K, Watanabe H, et al. Lung cancer patients with synchronous colon cancer. Mol Clin Oncol. 2018;8(1):137-140. http://doi.org/10.3892/mco.2017.1471 Villeneuve PJ, Sundaresan RS. Surgical management of colorectal lung metastasis. Clin Colon Rectal Surg. 2009;22(4):233-241. http://doi.org10.1055/s-0029-1242463 Motono N, Synchronous Lung Cancer with Bone Metastasis and Rectal Cancer: A Case Report. Annals of Clinical and Medical Case Reports. 2020; 4(2): 1-4. ACMCR-v4-1384.pdf (acmcasereport.org) Mulder SA, Kranse R, Damhuis RA, de Wilt JH, Ouwendijk RJ, Kuipers EJ, van Leerdam ME. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol. 2011 Oct;35(5):442-7. http://doi.org/10.1016/j.canep.2010.12.007 Yamanaka S, Sakamoto A, Tomoyasu H. [Synchronous multiple primary lung and colon cancers]. Kyobu Geka. 2013 Sep;66(10):882-5. Japanese. PMID: 24008636. [Synchronous multiple primary lung and colon cancers] - PubMed (nih.gov) Brouwer NPM, van der Kruijssen DEW, Hugen N, et al. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. Annals of Surgical Oncology. 2020 May;27(5):1580-1588. http://doi.org/10.1245/s10434-019-08100-5. Oweira H, Mehrabi A, Reissfelder C, Abdel-Rahman O. A Real-World, Population-Based Analysis of the Outcomes of Colorectal Cancer Patients with Isolated Synchronous Liver or Lung Metastases Treated with Metastasectomy. World J Surg. 2020;44(5):1604-1611. http://doi.org/10.1007/s00268-019-05353-9 Nozawa H, Sunami E, Nakajima J, Nagawa H, Kitayama J. Synchronous and metachronous lung metastases in patients with colorectal cancer: A 20-year monocentric experience. Experimental and Therapeutic Medicine. 2012 Mar;3(3):449-456. http://doi.org/10.3892/etm.2011.443. Rodriguez-Bigas MA, Lin EH, Crane CH. Surgical Anatomy. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Gaitanidis A, Alevizakos M, Tsaroucha A, Tsalikidis C, Pitiakoudis M. Predictive Nomograms for Synchronous Distant Metastasis in Rectal Cancer. J Gastrointest Surg. 2018 Jul;22(7):1268-1276. doi: http://doi.org/10.1007/s11605-018-3767-0. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4971114","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":348247877,"identity":"90d8eaab-414e-4a71-bbe7-026513a59d8e","order_by":0,"name":"Alejandro Cruz","email":"","orcid":"","institution":"University of Arizona, Tucson","correspondingAuthor":false,"prefix":"","firstName":"Alejandro","middleName":"","lastName":"Cruz","suffix":""},{"id":348247878,"identity":"53314857-50ac-4549-b2ca-441f8a2941e5","order_by":1,"name":"Mohammad Afaque Alam","email":"","orcid":"","institution":"Louisiana State University Health Sciences Center New Orleans","correspondingAuthor":false,"prefix":"","firstName":"Mohammad","middleName":"Afaque","lastName":"Alam","suffix":""},{"id":348247879,"identity":"e9d3a322-17cb-41f8-8ce9-6898bea7fc8e","order_by":2,"name":"Pamela Omesiete","email":"","orcid":"","institution":"University of Arizona, Tucson","correspondingAuthor":false,"prefix":"","firstName":"Pamela","middleName":"","lastName":"Omesiete","suffix":""},{"id":348247880,"identity":"9248dca0-92a3-4cc3-bf53-4ac17811eb27","order_by":3,"name":"Sabina Saeed","email":"","orcid":"","institution":"University of Arizona, Tucson","correspondingAuthor":false,"prefix":"","firstName":"Sabina","middleName":"","lastName":"Saeed","suffix":""},{"id":348247881,"identity":"76269024-5ba1-422f-86fe-e41db5187bd6","order_by":4,"name":"Manijeh Assar","email":"","orcid":"","institution":"University of Arizona, Tucson","correspondingAuthor":false,"prefix":"","firstName":"Manijeh","middleName":"","lastName":"Assar","suffix":""},{"id":348247882,"identity":"0437b5a7-302b-4d40-9fb6-cd19998f67ee","order_by":5,"name":"Mohammad Hamidi","email":"","orcid":"","institution":"University of Arizona, Tucson","correspondingAuthor":false,"prefix":"","firstName":"Mohammad","middleName":"","lastName":"Hamidi","suffix":""},{"id":348247883,"identity":"844ba863-8774-4cee-b0b9-e1d8441e8e45","order_by":6,"name":"Marlon Guerrero","email":"","orcid":"","institution":"University of Arizona, Tucson","correspondingAuthor":false,"prefix":"","firstName":"Marlon","middleName":"","lastName":"Guerrero","suffix":""},{"id":348247884,"identity":"80287727-5f21-4a0c-864d-9217a97f0835","order_by":7,"name":"Valentine Nfonsam","email":"data:image/png;base64,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","orcid":"","institution":"Louisiana State University Health Sciences Center New Orleans","correspondingAuthor":true,"prefix":"","firstName":"Valentine","middleName":"","lastName":"Nfonsam","suffix":""}],"badges":[],"createdAt":"2024-08-25 03:41:12","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4971114/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4971114/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":66848572,"identity":"379731a3-73cc-4bf1-b152-17041f6bb83b","added_by":"auto","created_at":"2024-10-17 06:25:05","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":232923,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eFlowchart of the enrollment process, tumor stages and treatment.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-4971114/v1/6b6395ffcb0f1a75a65c9982.png"},{"id":85353376,"identity":"e097de20-550b-4779-ad88-e3318bffe7f0","added_by":"auto","created_at":"2025-06-25 03:46:45","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":912481,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4971114/v1/88dacfb2-3d6f-463b-b54e-b31a9326c0d3.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Incidence, Treatment and Outcomes of Patients with Synchronous Lung and Colorectal Malignancies: A Nationwide Inpatient Sample Database (NIS) Analysis","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eLung Cancer (LC) remains the leading cause of cancer-related deaths, with Colorectal Cancer (CRC) being the third leading cause of cancer-related deaths in the US [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Patients diagnosed with metastatic CRC may have tumors arising in locations such as the liver, lungs, and peritoneum [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Although CRC and lung cancer are among the most common cancers worldwide, synchronous presentation of these cancers are not very common and not well studied.\u003c/p\u003e \u003cp\u003eClinically, synchronous cancers refer to the onset of a second primary cancer within 6 months of an initial cancer diagnosis or co-occurring. Although the condition is uncommon, there has been a rise in synchronous CRC cases in recent years. Insufficient data is available on the onset of synchronous cancer that this disease remains poorly understood [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. The rarity of this clinical presentation at the onset can often lead to delay of treatment or misdiagnosis of metastasis, rather than finding the cancers to be coinciding [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eImprovements in diagnostic modalities have contributed to the increased detection of synchronous CRCs [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Reported incidences range from 2.3\u0026ndash;12.4%. [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e] Additionally, the prevalence of synchronous CRC ranges from 1.1\u0026ndash;8.1% among all CRCs [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Despite the increased prevalence of the disease, the most appropriate treatment options, including surgical, remain uncertain. Previous studies have shown that the treatment for synchronous cancer is different in that it is done according to the distribution of lesions [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eSynchronous CRC differs from single origin cancer with regards to gender, age, location, as well as pathologic features [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Risk factors for this disease include inflammatory bowel disease, familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, hyperplastic polyposis, and microsatellite instability [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. A few case studies have demonstrated synchronous CRC in patients with liver, kidney, prostate, and lung cancers [\u003cspan additionalcitationids=\"CR9 CR10\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. A majority of synchronous CRC cancers occur in the liver, followed by the lung [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFew case reports have indicated synchronous CRC and LC with lesions located in the rectum and the lungs; nonetheless, this identified patient population remains low, and outcomes in patients with synchronous lung and CRC are not well described [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Our study aimed to describe the incidence, treatment, and outcomes of patients with synchronous lung and CRC. It is important to develop a better understanding of synchronous lung and CRC in order to further advance treatment options for those affected.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eDataset\u003c/h2\u003e \u003cp\u003eWe used the Nationwide Inpatient Sample (NIS) to analyze data from 2002 to 2012 retrospectively. The NIS is one of the largest all-payer national databases in the United States developed and maintained as a part of the Health Care Cost and Utilization Project (HCUP). The NIS database includes inpatient care information from community hospitals, and teaching medical centers; however, this database does not include data from long-term facilities. Every year, the NIS provides information on nearly 7\u0026nbsp;million unweighted discharges nationally. The use of the NIS database for this study followed regulations according to the data-use agreement from the HCUP. Ultimately, this study was reviewed by the University of Arizona\u0026rsquo;s Institutional Review Board and was determined to be exempt from the need for approval. Figure\u0026nbsp;1 shows a flowchart classifying patients based on the development of colorectal cancer (CRC) alone or synchronous CRC with simultaneous lung cancer from 2002 to 2012, as listed in the NIS database. Among the 1,198,421 patients admitted with a CRC diagnosis, 6,231 had synchronous lung cancer. The patients were further categorized by tumor stage and treatment strategies.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003ePatient population and Stratification\u003c/h2\u003e \u003cp\u003ePatients older the age of 18 presenting with CRC alone or synchronous CRC with simultaneous Lung Cancer were included in this study. Additionally, the codes for colon, rectal, and lung cancer were used for stratification using Ninth Revision of the International Classification of Disease Diagnosis (ICD-9 codes). To ascertain that only synchronous lung cancer patients were analyzed, metastatic lung cancer patients were excluded from the analysis. Thus, patients with ICD-9 CM code 197.0 were excluded from the analysis. 197.0: Secondary malignant neoplasm of the lung.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eVariables analyzed and Outcome Measures\u003c/h2\u003e \u003cp\u003eFrom the database analysis, we retrieved information on patient demographics (age, gender, race), insurance (Medicare, Medicaid, private/self-pay, other), income (lowest quartile vs. highest quartile), CRC location (hepatic flexure, transverse colon descending colon, sigmoid colon, cecum, \u003cspan refid=\"Sec10\" class=\"InternalRef\"\u003eappendix\u003c/span\u003e, ascending colon, splenic flexure, rectosigmoid, rectum, and anus), tumor stage (I, II, III, IV), treatment (chemotherapy, radiotherapy, colectomy, lobectomy), as well as treatment sequence (treatment of CRC first versus treatment of lung cancer first or supportive care alone).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eData with a normal distribution is reported as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (SD) for continuous variables, as median [interquartile range (IQR)] for continuous variables without normal distribution, and as proportions (% percentage) for the categorical variables. To analyze the differences between the two patient groups, we used a chi-square test for categorical variables, the Mann-Whitney U test for continuous nonparametric data, and an independent Student\u0026rsquo;s t-test for continuous parametric data.\u003c/p\u003e \u003cp\u003eA multivariate logistic regression was used to control for the following covariates: patient\u0026rsquo;s demographics, type of cancer, location of tumor, and the treatment sequencing and modality. First, we assessed the association between each covariate and the binary outcomes on a univariate level. Variables detected to have a p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.2 after performing the univariate analysis were selected for inclusion in the multivariable logistic regression model. Hosmer-Lemeshow goodness of fit test was used to assess the model fitness. The Hosmer-Lemeshow test exceeded 0.05 and the tolerance was greater than 0.1 for all independent variables with a variance inflation factor of less than 10.0. In this study, alpha was set at 5% and a value of p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant. All statistical analyses in our study were performed using the Statistical Package for Social Sciences (SPSS, version 24; SPSS, Inc).\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cp\u003eA total of 1,198,421 patients were admitted to a hospital with a diagnosis of CRC of which 6,231 were found to have synchronous lung cancer. In Table \u003cspan\u003e1\u003c/span\u003e, the demographics in patients who presented with CRC alone and synchronous CRC and Lung cancers were similar in average age, gender, whites, BMI, Medicare and Medicaid. There was a significant difference in patients with private insurance with about 8% with CRC alone versus 12% with synchronous CRC and Lung Cancer (p\u0026thinsp;=\u0026thinsp;0.01). In addition, there was a statistically significant difference in patients in the low-income quartile (24% vs 26%).\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"668\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eTable 1: Baseline Characteristics of the Study Sample\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eCRC\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eN=1,192,189\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eCRC + Lung Cancer\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eN=6,231\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eP-Value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eDemographics\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eAge, years \u0026plusmn; SD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e60\u0026plusmn;14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e61\u0026plusmn;11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eMale, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e75%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e74%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eWhite, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e67%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e68%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.38\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eBMI\u0026ge;30 kg/m\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e33%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e27%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.74\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eMedicare\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e62%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e61%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.63\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eMedicaid\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e30%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e27%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.87\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003ePrivate Insurance\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e12%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eLow Income Quartile\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e24%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e26%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCRC Location, %\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eHepatic Flexure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.17\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eTransverse Colon\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e4.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eDescending Colon\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e10%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026lt;0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eSigmoid Colon\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eCecum\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e7.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.64\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eAppendix\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.13\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eAscending Colon\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e10%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e6.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.87\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eSplenic Flexure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eRectosigmoid\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e79%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e78%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.14\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eRectum\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.56\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eAnal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.74\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eUnspecified\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e* p-values \u0026lt;0.05 is statistically significant\u003c/p\u003e\n\u003cp\u003eMost CRC patients (79%) had recto-sigmoid tumors. On the other hand, in synchronous CRC and lung cancer, the CRC location most involved was the descending colon (10%) and in unspecified locations (2.4%) when being compared to CRC cancer alone (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01). Additionally, most patients with synchronous malignancies (56%) had advanced CRC with non-small cell lung cancer (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01). In Table \u003cspan\u003e2\u003c/span\u003e, the analysis also showed that there were more patients diagnosed with stage II CRC cancer alone (42%) compared to those with synchronous CRC cancer and lung cancer (17%).\u003c/p\u003e\n\u003cdiv\u003e\n \u003ctable id=\"Tab2\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 2\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003eTumor Stage of the Study Sample\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003ccolgroup cols=\"4\"\u003e\u003c/colgroup\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eTumor Stage\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCRC\u003c/p\u003e\n \u003cp\u003eN\u0026thinsp;=\u0026thinsp;1,192,189\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCRC\u0026thinsp;+\u0026thinsp;Lung Cancer\u003c/p\u003e\n \u003cp\u003eN\u0026thinsp;=\u0026thinsp;6,231\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eP-Value\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.09\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eII\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e42%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e17%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u0026lt;\u0026thinsp;0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIII\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e21%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e23%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.77\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIV\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e31%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e56%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u0026lt;\u0026thinsp;0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\"\u003e* p-values\u0026thinsp;\u0026lt;\u0026thinsp;0.05 is statistically significant\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003eIn Table \u003cspan\u003e3\u003c/span\u003e, the majority of the patients with synchronous CRC cancer and lung cancer (54%) were treated with chemotherapy (P\u0026thinsp;\u0026lt;\u0026thinsp;0.01) while just 15% of this cohort of patients had a colectomy. In Table \u003cspan\u003e4\u003c/span\u003e, no significant difference was noted in the proportion of patients first treated for their CRC relative to those treated for their lung cancer first (p\u0026thinsp;=\u0026thinsp;0.21). Overall, there was a statistically significant difference in the mortality rate for synchronous CRC and lung cancer versus CRC alone (65% vs 54%).\u003c/p\u003e\n\u003cdiv\u003e\n \u003ctable id=\"Tab3\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 3\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003eTreatments of the Study Sample\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003ccolgroup cols=\"4\"\u003e\u003c/colgroup\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eTreatment\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCRC\u003c/p\u003e\n \u003cp\u003eN\u0026thinsp;=\u0026thinsp;1,192,189\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCRC\u0026thinsp;+\u0026thinsp;Lung Cancer\u003c/p\u003e\n \u003cp\u003eN\u0026thinsp;=\u0026thinsp;6,231\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eP-Value\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eChemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e36%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e54%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u0026lt;\u0026thinsp;0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRadiotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e17%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e16%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.07\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eColectomy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e25%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e15%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u0026lt;\u0026thinsp;0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eLobectomy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e16%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\"\u003e* p-values\u0026thinsp;\u0026lt;\u0026thinsp;0.05 is statistically significant\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cdiv\u003e\n \u003ctable id=\"Tab4\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 4\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003eTreatment Sequence of the Study Sample\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003ccolgroup cols=\"2\"\u003e\u003c/colgroup\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eTreatment Sequence\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCRC\u0026thinsp;+\u0026thinsp;Lung Cancer\u003c/p\u003e\n \u003cp\u003eN\u0026thinsp;=\u0026thinsp;6231\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eTreatment of Colon Cancer First\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e12%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eTreatment of Lung Cancer First\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e13%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSupportive Care Alone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e75%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cdiv\u003e\n \u003ctable id=\"Tab5\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 5\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003eOutcomes for Study Sample\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003ccolgroup cols=\"4\"\u003e\u003c/colgroup\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eOutcomes\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCRC\u003c/p\u003e\n \u003cp\u003eN\u0026thinsp;=\u0026thinsp;1,192,189\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCRC\u0026thinsp;+\u0026thinsp;Lung Cancer\u003c/p\u003e\n \u003cp\u003eN\u0026thinsp;=\u0026thinsp;6,231\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eP-Value\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eMortality, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e54%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e65%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt;\u0026thinsp;0.01*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\"\u003e* p-values\u0026thinsp;\u0026lt;\u0026thinsp;0.05 is statistically significant\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n \u003c/table\u003e\n\u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eOur study showed that synchronous CRC and lung cancer is not very common but has a significant mortality rate. The independent risk factors for CRC or lung cancer have previously been established. Cigarette smoking has been shown as a generally accepted risk factor, especially within lung cancer [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Previous studies have also demonstrated that obesity, diabetes, and high dietary meat intake are associated with an increased risk of colon cancer [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Multiple risk factors have also been found to contribute to the development of synchronous CRC. African American race, advanced age, high primary tumor grade and size, perineural invasion, elevated CEA, and existing liver metastasis are associated with synchronous CRC and lung tumors [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. The results of our study showed some differences when it comes to demographic factors that influence CRC and synchronous CRC and lung tumors (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Previous studies have also indicated a higher incidence of synchronous CRC among men, especially in patients over 70 years [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Our study further reinforces this significance, as the data shows a higher percentage of men (74%) than women are diagnosed with synchronous CRC and lung cancer. In our study, the average age of diagnosis for CRC alone or synchronous with lung cancer was around 60 and primarily occurring mostly in white individuals. Interestingly, our data showed that patients with private insurance and those within the low-income quartile were more likely to have synchronous CRC than CRC alone, which was statistically significant. This could be because the patients in low-income quartile might have more comorbidities due to poor health choices and because they might have less access to healthcare.\u003c/p\u003e \u003cp\u003eRegarding location, synchronous CRC with LC arises more commonly in the descending colon and unspecified areas in our group of patients. This differs from metastatic CRC to the lung. Previous studies have shown that rectal and left-sided colon cancer had more predilection for lung metastasis over other sites, such as liver and peritoneum (16). It is important to consider the different venous drainage systems of the colon\u0026mdash;the inferior rectum is drained to the systemic circulation via the inferior rectal veins while the rest of the colon drains to the portal system. This may explain why rectal tumors more commonly have metastasis to the lungs [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eOur study demonstrates that more than half the patients diagnosed with synchronous CRC and lung cancer had advanced-stage disease. This might be because these patients might have a more aggressive disease or have a predilection for cancer. The majority of synchronous CRC and lung cancer patients (75%) undergone supportive care alone. This is quite understandable because these patients had significantly advanced diseases. These patients were also more likely to undergo chemotherapy (54%) than colectomy (15%). Lung lobectomy was performed in 16% of the individuals with synchronous lung and CRC. Overall, synchronous CRC and lung cancer were found to have higher mortality rates than CRC alone. A previous study investigating treatment outcomes in synchronous CRC with lung cancer patients found that subjects who had undergone lung tumor resection had overall better survival than those who did not, with a hazard ratio of 0.482 [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. We were not able to determine this particular outcome in our study. Another study showed that synchronous CRC patients who had undergone pulmonary metastasectomy had a 65% 5-year survival rate [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. However, this study looked more are pulmonary metastasis and not primary lung cancer.\u003c/p\u003e \u003cp\u003eRegarding the treatment sequence, our study showed 12% of patients with synchronous CRC and lung cancer underwent treatment of their colorectal cancer first. In comparison, 13% underwent treatment for their lung cancer first. As previously mentioned, most patients underwent supportive care alone. In our study, we could not determine whether any of the patients underwent concurrent management of both lung and colorectal cancer. We assume that this possibly happened. Information on the time interval between colon resections and lobectomies was not available. In one case report study of synchronous CRC and lung cancer in a patient with adenocarcinoma in both locations, confirmed using immunostaining showing primary origins in each location, the patient underwent lobectomy and months later a colon resection was performed [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. This showed that both surgical procedures could be performed in a sequential manner.\u003c/p\u003e \u003cp\u003eOur study also demonstrates that patients with synchronous CRC and lung cancer have a higher mortality rate than those diagnosed with CRC alone (65% vs 54%). Our results are concurrent with other synchronous cancer studies, which have demonstrated worse outcomes of survival for synchronous CRC compared to CRC alone [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Due to lung cancer being the leading cause of cancer-related deaths in the US, this can be considered a contributing factor to the high mortality rate observed within synchronous cancer [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. One study of 3,102 patients followed over 76 months found that of the 9 patients that succumbed to their illness, all 9 deaths were directly associated to the patients\u0026rsquo; lung cancer [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Advanced staging (56%) can be another contributor to why higher mortality rates are seen amongst patients with synchronous CRC and lung cancer, as shown in our results. Our analysis shows that patients with synchronous CRC and lung cancer are more likely to present with stage IV than CRC alone.\u003c/p\u003e \u003cp\u003eOne of the inherent limitations of this study is that it is a retrospective analysis and there might be missing data. We could not review the histopathology of the CRC or lung cancer to determine synchronous primary lung cancer from metastatic lung cancer. However, we excluded from this study all the lung cancers that were coded with ICD-9 CM code 197.0, which represents metastatic disease to the lungs. Another limitation of this study was the lack of staging of primary lung cancer. The assumption would have been that a higher stage of lung cancer will likely have more contribution to patient mortality. This would have also been important in determining if the high mortality in the synchronous lung and colorectal cancer was due to colorectal cancer or lung cancer. Given the fact that lung cancer is the leading cause of cancer-related deaths in the US, it is reasonable to conclude a higher stage of synchronous lung cancer is more predictive of mortality than colorectal cancer is.\u003c/p\u003e"},{"header":"CONCLUSION","content":"\u003cp\u003eThe incidence of synchronous occurrence of CRC and lung cancer is low, but the mortality is very high. Diagnosis of synchronous cancer is typically incidental. These patients usually present with more advanced disease and mortality might likely be accentuated by lung cancer. Treatment options for these patients should be tailored to the individual patient. Genetic and epidemiological studies are required to elucidate the potential connection between lung and colon.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eFunding: No financial or proprietary interest in the subject matter or materials discussed in the manuscript.\u003c/p\u003e\n\u003cp\u003eConflicts of interest/Competing interest: There are no conflicts of interests to report.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAvailability of data and material: Nationwide Inpatient Sample database (2002-2012)\u003c/p\u003e\n\u003cp\u003eCode availability:\u0026nbsp;ICD-9 CM code 197.0\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cu\u003eAuthor\u0026rsquo;s contribution:\u0026nbsp;\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStudy Design and Conception: VN, MAA, PO, AC, MH, SS, MA, MG\u003c/p\u003e\n\u003cp\u003eData Acquisition: MAA, PO, AC, VN, MH\u003c/p\u003e\n\u003cp\u003eStatistical Analysis: MH, MAA\u003c/p\u003e\n\u003cp\u003eManuscript Writing: MAA, AC, VN, PO, MH, SS, MA, MG\u003c/p\u003e\n\u003cp\u003eCritical Revision: VN, MAA, AC, PO, MH, SS, MA, MG\u003c/p\u003e\n\u003cp\u003eFinal Approval: VN, MAA, AC, PO, MH, SS, MA, MG\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003csup\u003e*\u0026nbsp;\u003c/sup\u003eContributed Equally\u003c/strong\u003e (AC and MAA).\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eSiegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. http://doi.org/10.3322/caac.21590\u003c/li\u003e\n \u003cli\u003eSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. http://doi.org/10.3322/caac.21551\u003c/li\u003e\n \u003cli\u003eRiihim\u0026auml;ki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765. Published 2016 Jul 15. http://doi.org/10.1038/srep29765\u003c/li\u003e\n \u003cli\u003eLee BC, Yu CS, Kim J, et al. Clinicopathological features and surgical options for synchronous colorectal cancer. Medicine (Baltimore). 2017;96(9):e6224. http://doi.org/10.1097/MD.0000000000006224\u003c/li\u003e\n \u003cli\u003eHe W, Zheng C, Wang Y, et al. Prognosis of synchronous colorectal carcinoma compared to solitary colorectal carcinoma: a matched pair analysis. Eur J Gastroenterol Hepatol. 2019;31(12):1489-1495. http://doi.org/10.1097/MEG.0000000000001487\u003c/li\u003e\n \u003cli\u003eChin CC, Kuo YH, Chiang JM. Synchronous colorectal carcinoma: predisposing factors and characteristics. Colorectal Dis. 2019;21(4):432-440. http://doi.org/10.1111/codi.14539\u003c/li\u003e\n \u003cli\u003eLam AK, Chan SS, Leung M. Synchronous colorectal cancer: clinical, pathological and molecular implications. World J Gastroenterol. 2014;20(22):6815-6820. http://doi.org/10.3748/wjg.v20.i22.6815\u003c/li\u003e\n \u003cli\u003eBurlaka AA, Kolesnik OO. Parenchyma sparing multicomponent liver resection strategy for multiple bilobar synchronous colorectal cancer metastasis. Clin Case Rep. 2020;8(4):661-666. Published 2020 Feb 26. http://doi.org/10.1002/ccr3.2742\u003c/li\u003e\n \u003cli\u003eSakellakis M, Peroukides S, Iconomou G, Boumpoucheropoulos S, Kalofonos H. Multiple primary malignancies: a report of two cases. Chin J Cancer Res. 2014;26(2):215-218. http://doi.org/10.3978/j.issn.1000-9604.2014.02.15\u003c/li\u003e\n \u003cli\u003eJacobs CD, Trotter J, Palta M, et al. Multi-Institutional Analysis of Synchronous Prostate and Rectosigmoid Cancers. Front Oncol. 2020;10:345. Published 2020 Mar 24. http://doi.org/10.3389/fonc.2020.00345\u003c/li\u003e\n \u003cli\u003eKurishima K, Miyazaki K, Watanabe H, et al. Lung cancer patients with synchronous colon cancer. Mol Clin Oncol. 2018;8(1):137-140. http://doi.org/10.3892/mco.2017.1471\u003c/li\u003e\n \u003cli\u003eVilleneuve PJ, Sundaresan RS. Surgical management of colorectal lung metastasis. Clin Colon Rectal Surg. 2009;22(4):233-241. http://doi.org10.1055/s-0029-1242463\u003c/li\u003e\n \u003cli\u003eMotono N, Synchronous Lung Cancer with Bone Metastasis and Rectal Cancer: A Case Report. Annals of Clinical and Medical Case Reports. 2020; 4(2): 1-4. ACMCR-v4-1384.pdf (acmcasereport.org)\u003c/li\u003e\n \u003cli\u003eMulder SA, Kranse R, Damhuis RA, de Wilt JH, Ouwendijk RJ, Kuipers EJ, van Leerdam ME. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol. 2011 Oct;35(5):442-7. http://doi.org/10.1016/j.canep.2010.12.007\u003c/li\u003e\n \u003cli\u003eYamanaka S, Sakamoto A, Tomoyasu H. [Synchronous multiple primary lung and colon cancers]. Kyobu Geka. 2013 Sep;66(10):882-5. Japanese. PMID: 24008636. [Synchronous multiple primary lung and colon cancers] - PubMed (nih.gov)\u003c/li\u003e\n \u003cli\u003eBrouwer NPM, van der Kruijssen DEW, Hugen N, et al. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. Annals of Surgical Oncology. 2020 May;27(5):1580-1588. http://doi.org/10.1245/s10434-019-08100-5.\u003c/li\u003e\n \u003cli\u003eOweira H, Mehrabi A, Reissfelder C, Abdel-Rahman O. A Real-World, Population-Based Analysis of the Outcomes of Colorectal Cancer Patients with Isolated Synchronous Liver or Lung Metastases Treated with Metastasectomy. World J Surg. 2020;44(5):1604-1611. http://doi.org/10.1007/s00268-019-05353-9\u003c/li\u003e\n \u003cli\u003eNozawa H, Sunami E, Nakajima J, Nagawa H, Kitayama J. Synchronous and metachronous lung metastases in patients with colorectal cancer: A 20-year monocentric experience. Experimental and Therapeutic Medicine. 2012 Mar;3(3):449-456. http://doi.org/10.3892/etm.2011.443.\u003c/li\u003e\n \u003cli\u003eRodriguez-Bigas MA, Lin EH, Crane CH. Surgical Anatomy. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.\u003c/li\u003e\n \u003cli\u003eGaitanidis A, Alevizakos M, Tsaroucha A, Tsalikidis C, Pitiakoudis M. Predictive Nomograms for Synchronous Distant Metastasis in Rectal Cancer. J Gastrointest Surg. 2018 Jul;22(7):1268-1276. doi: http://doi.org/10.1007/s11605-018-3767-0.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Synchronous, Colorectal, Lung, Cancer","lastPublishedDoi":"10.21203/rs.3.rs-4971114/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4971114/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003ePurpose:\u003c/h2\u003e \u003cp\u003eOur study aims to describe the incidence, treatment and clinical outcomes of patients with synchronous lung, and colorectal cancer (CRC).\u003c/p\u003e\u003ch2\u003eMethods:\u003c/h2\u003e \u003cp\u003eWe conducted an 11-years analysis of the Nationwide Inpatient Sample (NIS) database (2002\u0026ndash;2012). All adult (age\u0026thinsp;\u0026ge;\u0026thinsp;18y) patients admitted with a diagnosis of CRC were included. Data abstracted include demographics, malignancy-related variables, treatment, and operative interventions. We excluded patients who had lung metastasis from CRC. Our primary outcome measures were the incidence of synchronous CRC and lung cancer, operative treatment patterns, and mortality.\u003c/p\u003e\u003ch2\u003eResults:\u003c/h2\u003e \u003cp\u003eOut of 1,198,421 patients admitted with a CRC diagnosis, 6,231 (0.52%) had synchronous lung cancer. Overall, mean age was 61\u0026thinsp;\u0026plusmn;\u0026thinsp;15y, 75% were male, and 63% were white. Most patients with synchronous malignancies (56%) had advanced CRC with non-small cell lung cancer (76%). The majority of CRC patients (79%) had recto-sigmoid tumors. Only 11.2% underwent surgical management. No significant difference was noted in the proportion of patients first treated for their CRC relative to those treated for their lung cancer first (p\u0026thinsp;=\u0026thinsp;0.21). The overall mortality rate was 54%.\u003c/p\u003e\u003ch2\u003eConclusion:\u003c/h2\u003e \u003cp\u003eThe incidence of synchronous occurrence of CRC and lung cancer is low, but the mortality is very high. Diagnosis of synchronous cancer is typically incidental. Treatment options for these patients should be tailored to the individual patient. Genetic and epidemiological studies are required to elucidate the potential connection between lung and colon cancer.\u003c/p\u003e","manuscriptTitle":"Incidence, Treatment and Outcomes of Patients with Synchronous Lung and Colorectal Malignancies: A Nationwide Inpatient Sample Database (NIS) Analysis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-17 06:25:01","doi":"10.21203/rs.3.rs-4971114/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1af9527b-6fcf-4401-bc2c-f7d6657b2385","owner":[],"postedDate":"October 17th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-06-25T03:38:38+00:00","versionOfRecord":[],"versionCreatedAt":"2024-10-17 06:25:01","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4971114","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4971114","identity":"rs-4971114","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}